---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-23-000047"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:04:55.494716+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbCellera cuts ~10% of workforce in reorganization; estimates $2.5M cash cost

## Summary
- Reduction impacts approximately 10% of employees to focus on clinical development and strategic partnerships.
- Estimated $2.5 million in cash expenses from the workforce reduction.
- Company reports over $1 billion in available liquidity, sufficient for strategy beyond 3 years.
- Reorganization aims to increase operational efficiency and prioritize internal drug development.

## SEC filing metadata
- accession: 0001703057-23-000047
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000047/0001703057-23-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000047/abcl-20231128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-23-000047
- JSON: https://secwatch.observer/filing/0001703057-23-000047.json
- Plain text: https://secwatch.observer/filing/0001703057-23-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.